# Oviva Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oviva-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.ovivatx.com
- Total disclosed funding: $12M
- Latest round: Seed (May 19, 2022)
- Investors on record: 1

## About

Founded in 2021 and based in New York, US, Oviva Therapeutics, Inc. is a majority-owned pipeline company (PipeCo) of Cambrian Biopharma, a multi-asset longevity biotech company developing therapeutics to first cure diseases and then develop treatments to prevent conditions from occurring. In May 2022, Oviva Therapeutics, Inc. raised USD 11.5 million in Seed funding from Cambrian Biopharma. Daisy Robinton (CEO), David Pépin, and Patricia K. Donahoe are the co-founders of the company.

The company is developing a drug that targets folliculogenesis, the process by which ovarian follicles, each containing a single egg, mature and eventually ovulate. The firm addresses women’s health by expanding funding, research, and clinical development.

The organization plans to use the May 2022 funding to develop treatments to improve the health span, which is the period during which women can live in good health.

## Funding rounds

- Seed, May 19, 2022, $12M — Cambrian Biopharma

## Investors

- Cambrian Biopharma (https://capitalatlas.ai/funds/cambrian-biopharma) — Seed